IRL receives MPA approval and initiates Phase I trials with IRL752, its second compound reaching clinical development

February 3, 2016

IRL has received approval from Läkemedelsverket (the Swedish MPA) and Regionala Etikprövningsnämnden, EPN, (the ethics committee, Uppsala) to conduct Phase I clinical trials with IRL752. IRL now initiates a Phase I clinical study program with IRL752, a cortical enhancer designed to treat Behavioral and Psychological Symptoms of Dementia (“BPSD”) and attention disorders. The first Phase I studies will evaluate safety, tolerability and pharmacokinetics.